Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
NCT00842348
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
89
Enrollment
INDUSTRY
Sponsor class
Conditions
Non Functioning Entero-pancreatic Endocrine Tumour
Interventions
DRUG:
lanreotide (Autogel formulation)
Sponsor
Ipsen